A One-Year, Randomized, Double-Blind, Placebo-Controlled Trial of Rosiglitazone in Non-Alcoholic Steatohepatitis
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study is intended to find out whether treatment with rosiglitazone improves the state of
the liver and related blood markers in patients with nonalcoholic steatohepatitis (NASH).